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Abstract Neuronal Cdc2-like kinase (Nclk) can be stimulated
by heparin in a substrate-dependent manner. While phosphoryla-
tion of tau is markedly enhanced by heparin, phosphorylation of
histone H1 by Nclk is essentially unaffected. A histone H1
peptide, HS(9^18) : PKTPKKAKKL, and its substitution
analogues were used to examine the basis of the differential
heparin effect. In the presence of heparin, the phosphorylation
site specificity of Nclk is altered and only proline immediately
following the phosphorylation site is still an essential substrate
determinant. This change in the site specificity may adequately
account for the differential heparin effect on histone H1 and tau
phosphorylation.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Neuronal Cdc2-like kinase (Nclk) is a proline-directed Ser/
Thr kinase composed of Cdk5 and p25/p35 [1^3]. Its primary
phosphorylation sequence has been characterized as S/T-P-X-
H/R/K (single amino acid symbols, X for any amino acid) by
independent studies using systematically substituted peptide
substrates and an oriented degenerate peptide library [4,5].
In addition to the requirement of a Pro at the position +1
and a basic residue (Lys, Arg or His) at the position +3
relative to the phosphorylation site, a string of positively
charged residues carboxyl terminal to the minimal phospho-
rylation sequence markedly enhances the phosphorylation
e⁄ciency of the substrate peptides [4].
Several lines of evidence have suggested that the microtu-
bule associated protein tau is a physiological substrate of Nclk
[6,7]. Tau is hyperphosphorylated in brains of Alzheimer’s
disease patients and the phosphorylation is essentially found
on proline-directed Ser/Thr residues [8]. However, most of the
tau phosphorylation sites fall into the S/T-P-X1-X2 (X2 is not
a basic amino acid) motif, which is a poor substrate sequence
of Nclk. It has been shown most recently that the Nclk-cata-
lyzed phosphorylation of tau is dramatically enhanced by hep-
arin [9]. Tau was observed to co-localize with sulfated glyco-
saminoglycans such as heparan sulfate in Alzheimer’s brains
[10,11]. Moreover, the binding of heparin or heparan sulfate
to tau prevents tau from binding to microtubules and induces
microtubule disassembly, suggesting that heparin or heparan
sulfate plays important roles in neuro¢brillary pathology [10].
In the present study, we observed that the e¡ect of heparin on
Nclk activity depended strongly on protein substrates. While
tau phosphorylation by Nclk was dramatically enhanced by
heparin, the activity of Nclk towards histone H1 was essen-
tially una¡ected. Using systematic analogues of the Nclk sub-
strate peptide from histone H1, the substrate-dependent stim-
ulation of Nclk by heparin was analyzed in detail. The result
shows that heparin caused a change of the Nclk phosphory-
lation site motif from S/T-P-X-K/R to S/T-P.
2. Materials and methods
2.1. Phosphorylation reactions
Nclk applied in this study was a reconstituted enzyme from bacte-
rially expressed Cdk5 and p25 [12]. Puri¢ed recombinant tau was a
441-amino acid isoform of human tau (hT40) [13]. Heparin was pur-
chased from Sigma. Phosphorylation of a histone H1 peptide HS(9^
18) (PKTPKKAKKL) and its analogues was performed as described
previously [4]. Kinetic constants were determined from Lineweaver-
Burk plots. Tau phosphorylation was carried out following the pro-
cedure of the peptide phosphorylation.
2.2. Binding of Nclk to heparin-Sepharose
170 Wg GST-Cdk5 was mixed with 200 Wg GST-p25 and 3.7 units of
thrombin (Sigma) in 0.2 ml PBS. The sample was allowed to sit at
room temperature for 2 h for reconstitution of Nclk and cleavage of
GST. The mixture was diluted to 1 ml with a column bu¡er (20 mM
MOPS, pH 7.4, 1 mM DTT, and 1 mM EDTA) before loading onto a
heparin-Sepharose CL-6B (Pharmacia) column (0.3 ml of bed vol-
ume), which was pre-equilibrated with the column bu¡er. The column
was then sequentially washed with 10 bed volumes of the column
bu¡er containing NaCl at the following conditions: 0, 0.15 M, 0.3
M, 0.5 M, and 1.0 M. Aliquots from each collected fraction were
measured for kinase activity by phosphorylation of the histone H1
peptide HS(9^18). Immunoblots were performed with monoclonal and
polyclonal antibodies recognizing Cdk5 and p25, respectively. The
blots were visualized by enhanced chemiluminescence (Amersham
Life Science, Inc.).
3. Results and discussion
3.1. Di¡erential e¡ects of heparin on tau and histone H1
phosphorylation
Among in vitro protein substrates identi¢ed for Nclk, his-
tone H1 is phosphorylated with the highest e⁄ciency. Tau has
been suggested as a physiological substrate of Nclk, but it is
phosphorylated in vitro at a slow rate [7]. Very recently, Ha-
segawa et al. have shown that Nclk-catalyzed phosphorylation
of tau can be stimulated by heparin [9]. As shown in Fig. 1,
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heparin stimulates the phosphorylating activity of Nclk to-
wards a recombinant human tau protein in a dose-dependent
manner with the maximal stimulation achieved at about 10
Wg/ml heparin. Under this condition, the tau phosphorylation
rate was increased by approximately 12-fold. In contrast,
Nclk-catalyzed histone H1 phosphorylation was essentially
una¡ected (Fig. 1), indicating that the heparin e¡ect on the
Nclk activity depends on the protein substrate applied in the
phosphorylation reaction. Previous studies have shown that
Nclk catalyzes tau phosphorylation to a stoichiometry of 3.8
mol of phosphate/mol of tau at seven sites: Ser-195, Ser-202,
Thr-205, Thr-231, Ser-235, Ser-396, and Ser-404 [7]. In the
presence of heparin, tau becomes more heavily phospho-
rylated by Nclk to about 12 mol of phosphate/mol of tau,
indicating that additional sites in tau are phosphorylated [9].
In fact, phosphorylation of some other sites besides these
seven residues was observed in the presence of heparin [9].
3.2. E¡ect of heparin on synthetic peptide phosphorylation
Synthetic peptides are useful tools for studies of phospho-
rylation site speci¢city. We have previously shown that a syn-
thetic peptide derived from the Nclk phosphorylation site in
histone H1, HS(9^18): PKTPKKAKKL, has essentially the
same substrate activity for Nclk as histone H1 protein [4].
Using a set of substitution analogues of the HS(9^18) peptide,
a number of amino acids in the peptide have been found as
determinants of Nclk substrate activity [4]. These include
Pro(+1) and Lys(+3) as strong determinants whose substitu-
tions result in elimination of the substrate activity, and
Pro(32), Lys(+5) and Lys(+6) as weak determinants (Fig.
2A). As shown in Fig. 2B, heparin displays little activating
activity towards Nclk when the peptide HS(9^18) was used as
a substrate, but it greatly stimulates the Nclk activity towards
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Fig. 1. E¡ect of heparin on phosphorylation of tau and histone H1
by Nclk. 0.3 Wg of tau or histone H1 protein was phosphorylated
by Nclk in the presence of di¡erent amounts of heparin. The phos-
phorylation rates in the absence of heparin are 0.13 pmol PO4/min
of tau and 15.72 pmol PO4/min of histone H1. The phosphorylation
rates in the presence of heparin are expressed as percentages of the
respective rates in the absence of heparin. The dashed line and open
circles represent phosphorylation of histone H1. The solid line and
circles are the reactions of tau.
Fig. 2. E¡ect of heparin on phosphorylation of the S/T-P-X-K and
S/T-P-X1-X2 peptides by Nclk. A: The consensus sequence motif of
Nclk substrates. Outlined letters in the sequence are residues crucial
for the substrate activity. B: Phosphorylation of HS(9^18)
(PKTPKKAKKL) and its analogue HS(9^18)A14 (PKTPKAAK-
KL). HS(9^18) and HS(9^18)A14 contain the S/T-P-X-K and S/T-P-
X1-X2 motifs, respectively. 5 WM of the peptides and di¡erent
amounts of heparin as indicated were applied in the reactions. The
phosphorylation rates are expressed as percentages of the respective
rates without heparin, which are 2.91 pmol PO4/min of HS(9^18)
and 0.21 pmol PO4/min of HS(9^18)A14. Dashed line and open
circles represent the reactions of HS(9^18). Solid line and circles are
the reactions of HS(9^18)A14.
Fig. 3. Relative phosphorylation rates of the peptide analogues of HS(9^18) with and without heparin. Phosphorylation of the synthetic pep-
tides was performed with reconstituted Nclk and 5 WM of HS(9^18) or its analogues. The phosphorylation rates are expressed as percentages
of phosphorylation of the parent peptide HS(9^18) in the absence of heparin. Shaded bars represent the phosphorylation in the absence of
heparin, and solid bars are the reactions in the presence of 15 Wg/ml heparin. Underlined residues are substitutions from the parent peptide.
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the Lys(+3) substituted peptide HS(9^18)A14, indicating that
the phosphorylation site speci¢city was modi¢ed by heparin.
A set of histone H1 peptide analogues was used to further
characterize the heparin e¡ect on Nclk phosphorylation site
speci¢city. Fig. 3 shows that, in general, phosphorylation of
the better Nclk substrates are not or only slightly a¡ected by
heparin, whereas heparin signi¢cantly stimulates phosphoryl-
ation of many of the poor substrates. Kinetic characterization
of the peptide phosphorylation has revealed that the stimula-
tion e¡ect of heparin is due to pronounced decrease in Km
values (Table 1). In fact, heparin caused Vmax values to de-
crease somewhat rather than to increase. An important con-
sequence of this substrate sequence-dependent heparin e¡ect is
that the consensus motif of the Nclk phosphorylation se-
quence is altered from S/T-P-X-K/R/H to S/T-P by heparin.
It eliminates the strong dependence of a basic residue (Lys/
Arg/His) at the position +3 in its phosphorylation sequence,
and e¡ects of most of the secondary substrate determinants
on the Nclk activity. On the other hand, some basic features
of its substrate speci¢city which include the speci¢city for Ser
or Thr but not Tyr, and the dependence on Pro(+1) are in-
dependent of heparin.
3.3. Direct interaction between Nclk and heparin
An e¡ector of a protein kinase reaction may exert its action
by binding either to the kinase or to the protein substrate,
termed enzyme-directed or substrate-directed e¡ect respec-
tively. Synthetic peptide substrates can be applied to distin-
guish the two mechanisms. It is reasonable to assume that
peptide substrates that contain minimal structures required
for substrate recognition are unlikely to bind to the e¡ector.
The observation that heparin can stimulate the Nclk activity
towards the peptide substrates suggests that heparin stimu-
lates Nclk in an enzyme-directed mechanism. To provide di-
rect demonstration of the physical interaction between Nclk
and heparin, a heparin-Sepharose column was used to isolate
Nclk from a crude sample that was reconstituted by incubat-
ing a mixture of bacterially expressed GST-Cdk5 and GST-
p25 with thrombin. The sample was applied to the column in
a bu¡er condition similar to that of the Nclk kinase reactions.
The column was then washed with the same column bu¡er,
and eluted step-wise with the bu¡ered solutions containing
0.15 M, 0.3 M, 0.5 M and 1.0 M NaCl. The eluents were
analyzed for the kinase activity of Nclk. Fig. 4A shows that
essentially all of the kinase activity was bound to the a⁄nity
column and most of the bound activity was eluted at 0.3 M
NaCl. As reported previously, bacterially expressed GST-
Cdk5 and GST-p25 contained large amounts of partially pro-
teolyzed and incorrectly folded proteins which were inactive
[12]. Most of the inactive species of the bacterially expressed
Nclk subunits appear not to bind to heparin-Sepharose. As
shown in Fig. 4B and C, most of the bacterially expressed
Cdk5 and p25 detected by the respective antibodies was found
in the £ow-through fraction which displayed little kinase ac-
tivity. The apparently speci¢c interaction between heparin and
active Nclk suggests that a heparin-Sepharose column may be
used to purify active Nclk from the crude sample reconsti-
tuted from its subunits.
In summary, we show in this study that heparin displays
di¡erent e¡ects on phosphorylation of tau and histone H1.
Using synthetic peptides as model protein substrates, the dif-
ferential e¡ect of heparin on the Nclk activity is shown to be
due to the di¡erence in phosphorylation site structures of the
two proteins. The substrate motif of Nclk is altered from S/T-
P-X-K/R/H to S/T-P by heparin. This heparin e¡ect is at least
partially attributed to its direct binding to Nclk. On the other
hand, the direct interaction between tau and heparin has also
been demonstrated and heparin stimulation of tau phospho-
FEBS 19863 20-2-98
Table 1
In£uence of heparin on kinetic parameters of Nclk
Km (WM) Vmax (% of control) Vmax/Km (% of control)
3Heparin +Heparin 3Heparin +Heparin 3Heparin +Heparin
HS(9^18) 14 6 100 97 100 226
HS(9^18)A13 61 11 124 84 28 107
HS(9^18)A14 339 15 106 40 4 37
HS(9^18)A16 29 3 95 60 46 280
HS(9^18)A17 24 3 100 63 58 294
HS(9^18)A16A17 163 21 78 59 7 39
Kinetic parameters were determined with reconstituted Nclk in the absence or presence of 15 Wg/ml heparin. Vmax and Vmax/Km were expressed as
relative rates (%) to those of the parent peptide HS(9^18) in the absence of heparin.
Fig. 4. Binding of Nclk to heparin-Sepharose. A: Kinase activity of the column fractions. The column was sequentially washed at di¡erent salt
conditions as indicated. 15 Wl aliquots from each fraction were subjected to a kinase assay using the substrate HS(9^18). B and C are immuno-
blots with antibodies recognizing Cdk5 and p25, respectively. os is the sample loaded on the column. FT is the £ow-through.
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rylation by a few other protein kinases has been reported,
thus suggesting that contribution of the heparin-tau interac-
tion to the kinase activation could not be completely ruled out
[14^17]. Therefore, heparin may facilitate the Nclk-catalyzed
tau phosphorylation by a¡ecting both the enzyme and the
substrate. Tau and heparan sulfate have been shown to co-
exist in neuro¢brillary tangles. Our ¢ndings indicate that an
increased level of sulfated glycosaminoglycans in neurons may
account for the aberrant Nclk activity and hyperphosphoryl-
ation of tau in the development of Alzheimer’s disease.
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